Clinical Trial Update: 4SCAR-T Therapy Post CD19-targeted Immunotherapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for 4SCAR-T therapy targeting CD19-negative B-cell malignancies across Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cd19-negative B-cell Malignancies

Drugs mentioned

• 4SCAR-T therapy

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: CD19 Negative B-cell Malignancies | Phase 1, Phase 2 | Status: UNKNOWN